journal
The Emergence of Non-Albicans Candidemia and Evaluation of HiChrome Candida Differential Agar and VITEK2 YST® Platform for Differentiation of Candida Bloodstream Isolates in Teaching Hospital Kandy, Sri Lanka
Area/Stream: Immunology and Microbiology, Authors: Mahen Kothalawala, J. A. A. S. Jayaweera, Sinnapoo Arunan, Anuradha Jayathilake Keywords: Candidemia: non-albicans candida sp., Emergence, Risk factors and anti-fungal resistanceJournal Name: BMC Microbiology Year:2019, Month:June, Volume: 19, Issue: Page No: 136 (2019) , ISSN: 1471-2180, DOI/Link:https://link.springer.com/article/10.1186/s12866-019-1518-3Abstract:
Candidemia is an emerging hospital-acquired bloodstream infection (BSI). It is common among severely ill and immunocompromised patients. Even following appropriate therapy in candidemia, recent studies reveal relative high mortality (40%). The global incidence of candidemia shows an incline. In Sri Lanka, candida speciation often difficult where basic facilities are less available. We have compared the risk factors, epidemiology, demography, and performance of HiChrome Candida differential agar (HiCA) characteristics with the VITEK2 YST platform for differentiation of Candida albicans (CA) and non-albicans candida (NAC) from blood culture isolate. This is a laboratory-based cross-sectional study. Positive aerobic BACTEC blood cultures having yeast were identified using HiCA and VITEK2® platform. Epidemiology, risk factors, and clinical outcomes were compared between CA and NAC bloodstream isolates. Out of 120 positive yeast samples, VITEK2® has identified 110 (92%) as Candida sp. From that CA-34 (31%) and NAC-76 (69%) were isolated. Candidemia following NCA in neonates (p=0.02), infants (p=0.04) and adults (p?=?0.02) in ICU and immunocompromised patients were significantly higher. Compared to CA, NAC bacteremia period prevalence (0.00041%) and incidence (0.23 per 100,000-person-years) was significantly high (p=0.03). NAC 48 (63%) isolates were resistance to azoles. Exposure to antifungals (odds ratio (OR); p=0.03), prolonged intensive care stay >14days (OR-3.3; p=0.04), having a central venous line for >?8?days (OR-4.3; p=0.03) and on immunosuppressive treatment (OR-2.4; p=0.04) was significantly poses risk for NAC candidemia. Sen day mortality was significant among non-albicans cases (p=0.03) while 30-day mortality was significant among albicans cases (p=0.04). Compared to VITEK2®, the HiCA method was 93% sensitive and 93% specific in detecting CA. Compared to CA, candidemia following NAC was high. NAC isolates were having a high percentage of fluconazole and voriconazole resistance. VITEK2 YST® platform provides antifungal susceptibility with minimal inhibitory concentration (MIC). Impact, this would highlight the use of rapid candida identification flat form with MIC to direct appropriate antifungals for candidemia. For that implementation of novel diagnostic facilities like the VITEK2 YST platform at a tertiary care facility is demanding.
Cite this: Mahen Kothalawala, J. A. A. S. Jayaweera, Sinnapoo Arunan, Anuradha Jayathilake,"The Emergence of Non-Albicans Candidemia and Evaluation of HiChrome Candida Differential Agar and VITEK2 YST® Platform for Differentiation of Candida Bloodstream Isolates in Teaching Hospital Kandy, Sri Lanka", BMC Microbiology, 19, , June, 2019, 136 (2019) , 1471-2180, https://link.springer.com/article/10.1186/s12866-019-1518-3
Views: 4252
Download File
News
